Switching off insatiable hunger

A new drug to help young patients with genetic obesity

More

Revolutionary milk analysis platform allows for multiplex analysis of 100 antibiotic residues and toxins in a single test

Unisensor produces the lateral flow biosticks for its unique Extenso platform with SCIENION’s unrivalled sciFLEXARRAYER ultra-low volume dispensers

More

NOXXON PHARMA N.V. REPORTS 2017 FINANCIAL RESULTS

Year marked by advance of clinical strategy

More

TU Berlin start-up Cellbricks wins World Summit Award

More

MOLOGEN reached key strategic milestones and successfully implements capital measures in 2017

First licensing agreement for lead compound lefitolimod concluded | Significant progress in studies | Company funding secured until the end of 2018 through successful capital measures

More

SPARK project receives millions in funding for a new epilepsy therapy

Charité clinician Regine Heilbronn and her research team convince the Federal Ministry of Education and Research (BMBF) at the GO-Bio Competition, daring to take the leap from the laboratory to medical application. The scientists were chosen for...

More

ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project

Berlin, Germany, April 18th, 2018

More

New funding for Captain T Cell

The MDC start-up project “Captain T Cell” has been awarded several million Euros from the German Federal Ministry of Education and Research (BMBF) as part of its GO-Bio funding initiative. The aim of the project is to develop new cancer-fighting...

More

The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK

Following approval in the UK in 2017, Humedics has now also received Marketing Authorization for its diagnostic agent, LiMAxetin®, in Germany and Austria.

 

More

CO.DON - successful conclusion of Phase II trial “co.dis” demonstrates efficacy and safety of the EU-authorised pharmaceutical product Spherox

After five years of follow-up observation, CO.DON AG has brought the Phase II clinical trial “co.dis” to a successful close. In the long-term clinical study 75 patients aged between 18 and 50, with cartilage defects in the knee, were treated with the...

More
Show more items